Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.27 | N/A | -12.99% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.27 | N/A | -12.99% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance. They did not provide any forward guidance, indicating uncertainty in future results.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
PTC Therapeutics reported a loss that was slightly worse than expected, leading to a 2.24% decline in stock price. The lack of revenue figures and guidance adds to investor uncertainty. Overall, the company faces challenges in improving its financial outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HUMANA INC
Nov 6, 2015